Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
about
Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Busulfan in hematopoietic stem cell transplantationPopulation pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseasBusulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Busulfan in hematopoietic stem cell transplant setting.Granulocyte colony-stimulating factor (G-CSF) promotes spermatogenic regeneration from surviving spermatogonia after high-dose alkylating chemotherapy.Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.
P2860
Q33978951-C8A1E856-5B19-4A4E-9D83-A76C8F27E396Q34668052-1066CCFA-3567-44DF-B4CA-4F2759D7B107Q35126138-8BC45354-5848-42BD-97A2-74158AD6A447Q35770722-A9685D80-FBD8-49AE-BBDA-DE3518D8379DQ36125427-AEA95BB9-85DC-461F-B773-B5F10BD7B139Q36264692-01DA6F3F-7266-4DD6-8892-B48EA6E97CA8Q36473125-2335777D-2AE6-4D56-941B-C9287B0C12A6Q36792760-58DB6563-0699-4FCE-9E33-2B3294CB6C34Q37370649-F8A3A8C0-3B91-45CB-AADB-EB04FC83F715Q37554387-728C3523-F14C-4145-A6C2-F6086CEDB4D9Q37579159-EDE553D4-B36D-4927-B633-DBB04D99C26CQ45306078-35338890-578D-403C-9E0A-A109E396CF3AQ46138906-D091D735-C23E-4301-A35B-9098B7ADB6F2Q51146472-662E64B2-20A1-452F-B784-702FFD39CD47
P2860
Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Intraindividual variability in ...... dose and first dose strategy.
@en
Intraindividual variability in ...... dose and first dose strategy.
@nl
type
label
Intraindividual variability in ...... dose and first dose strategy.
@en
Intraindividual variability in ...... dose and first dose strategy.
@nl
prefLabel
Intraindividual variability in ...... dose and first dose strategy.
@en
Intraindividual variability in ...... dose and first dose strategy.
@nl
P2093
P1433
P1476
Intraindividual variability in ...... dose and first dose strategy.
@en
P2093
Celeste Lindley
Don Garbriel
Donald Harvey
Jodi Decker
Joseph Wiley
Stacy Shord
Suzanne Kirby
Thomas Shea
William P Petros
P304
P356
10.1097/01.CAD.0000127145.50172.51
P577
2004-06-01T00:00:00Z